Opportunities Preloader

Please Wait.....

Report

India Malaria Vaccine Market By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Report I 2025-01-10 I 80 Pages I TechSci Research

India Malaria Vaccine Market was valued at USD 38.21 million in 2024 and is expected to reach USD 47.21 million by 2030 with a CAGR of 3.59% during the forecast period. The Rising awareness among people for early detection and treatments coupled with the rising number of people suffering from malaria are expected to augment the growth of the India malaria vaccine market. Malaria is caused by a parasite called Plasmodium, which is transmitted to humans through the bites of infected mosquitoes. Malaria is preventable and treatable, but the development of effective vaccines is essential to control and ultimately eliminate this disease. Growing incidences of malaria in the country is a major factor, which is surging the demand for effective malaria vaccines. These malaria vaccines are vaccines that are designed to prevent or reduce the severity of malaria, a disease caused by parasites that are transmitted to humans through the bites of infected mosquitoes. Furthermore, there are various other factors which are supporting the growth of India malaria vaccine market such as growing government initiatives, affordable vaccines, rising advancements in biotechnology, and others.
Key Market Drivers
Rise in Occurrences of Malaria
The high burden of malaria in India is one of the main drivers of the demand for malaria vaccines. Malaria remains a significant public health issue in the country, with millions of cases reported each year, particularly in rural and underprivileged areas. Despite significant efforts to control the disease through vector control, diagnosis, treatment, and health education, malaria remains a major cause of morbidity and mortality in India. Therefore, there is a surge in demand for the malaria vaccines in the country. The development of an effective malaria vaccine has the potential to significantly reduce the burden of malaria in India and other malaria-endemic countries. Thus, malaria vaccine would provide a highly effective tool for preventing malaria infection, particularly in high-risk populations, such as children under five and pregnant women. It would also reduce the number of cases of severe malaria and the associated morbidity and mortality. According to the World Health Organization (WHO), India accounted for 3% of the global malaria burden in 2019, with an estimated 247 million cases of malaria.
Moreover, the burden of malaria in India is particularly high in the states of Odisha, Chhattisgarh, Jharkhand, and the northeast region of the country. These areas are characterized by high rates of poverty, poor sanitation, and a lack of access to healthcare, which contribute to the persistence of malaria. Therefore, the rising prevalence of malaria is expected to bolster the growth of the India malaria vaccine market in the upcoming years.
Increasing Government Support
Increasing government support is one of the crucial factors for the growth of India's malaria vaccine market. The Indian government has recognized the importance of malaria prevention and control and has implemented several initiatives to address the high burden of malaria in the country. The government has also launched several awareness campaigns to promote the use of these malaria prevention and control measures. In addition to these initiatives, the Indian government has provided support for the development of malaria vaccines through various research and development programs. For instance, in 2022, the Ministry of Health and Family Welfare of India launched a campaign named Jan Abhiyaans with log bhaagidari (people's participation) to enthuse and engage people and communities to ensure that their neighborhoods, premises, and homes for vector control and elimination.
Furthermore, the Indian government has also introduced policies to support the manufacturing of vaccines within the country. The government's support for malaria vaccine research, development, and manufacturing has helped to create a favorable environment for the growth of India's malaria vaccine market. The government's initiatives have helped to attract investment in malaria vaccine research and development, and the policies supporting the manufacturing of vaccines within the country have helped to create a competitive and vibrant vaccine manufacturing industry in India.
Key Market Challenges
Regulatory and Approval Challenges
One of the major challenges facing the India malaria vaccine market is the complex and time-consuming regulatory approval process. India has a large and diverse population with varying levels of malaria transmission, and the regulatory landscape must account for these factors when evaluating malaria vaccine candidates. The rigorous testing and approval process for vaccines, especially in the context of a disease like malaria, which has multiple strains and geographical variations, complicates the development timeline. Additionally, the lack of a streamlined and unified regulatory approach across states can further delay vaccine distribution. India also faces challenges related to public health infrastructure, which can affect the smooth execution of large-scale clinical trials, data collection, and post-marketing surveillance. With the demand for timely malaria vaccination programs, the delay in regulatory approvals can hinder the ability to address public health concerns effectively. Furthermore, variations in vaccine efficacy due to local conditions, such as resistance to certain strains of malaria, pose additional challenges for obtaining regulatory approval for vaccines that can be widely used across the country.
Distribution and Accessibility Issues
Another significant challenge facing the malaria vaccine market in India is the distribution and accessibility of the vaccine, especially in rural and remote regions. Despite India's progress in healthcare, a large portion of its population still lives in areas where access to healthcare facilities is limited, making it difficult to implement widespread vaccination campaigns. The cold chain logistics required for storing and transporting vaccines, especially in regions with inadequate infrastructure, further exacerbates the issue. Moreover, the affordability of malaria vaccines is a critical concern, as many rural populations may not have the financial means to access vaccines, particularly in areas with high malaria burden. Government health initiatives and collaborations with international organizations like the World Health Organization (WHO) are crucial to overcoming these barriers, but challenges in funding, distribution networks, and local health system capacities still persist. Ensuring equitable access to malaria vaccines across all regions of India remains a complex task that requires overcoming both logistical and economic hurdles.
Key Market Trends
Growing Awareness About the Importance of Malaria Treatment
Growing awareness among people about the importance of malaria treatment is a significant factor that can contribute to the growth of the India malaria vaccine market. In recent years, there has been growing awareness among people about the importance of malaria prevention, diagnosis, and treatment. This growing awareness has been supported by government initiatives and public health campaigns aimed at educating people about the disease and its prevention and treatment. As more people become aware of the importance of malaria prevention and treatment, there is a greater demand for effective tools for malaria control, including vaccines. Also, the growing awareness among people about the importance of malaria treatment and prevention is also creating a favorable environment for investment in malaria vaccine research and development. Investors and stakeholders are increasingly recognizing the potential of the malaria vaccine market, and the growing demand for malaria vaccines is likely to drive investment in this area. Furthermore, the growing awareness about the importance of malaria treatment is also creating a demand for affordable and effective malaria vaccines. This demand is particularly significant in India, where access to healthcare is often limited in rural and underprivileged areas. Affordable and effective malaria vaccines can help to reduce the burden of malaria in these areas and improve access to healthcare for vulnerable populations.
Growing Research & Development Activities
Research and development (R&D) are a crucial factor that can significantly contribute to the growth of the India vaccine market. R&D plays a vital role in the development of vaccines, including malaria vaccines. In recent years, there has been a significant increase in R&D investment in India. The Indian government has implemented several initiatives to promote R&D in various sectors, including healthcare. For example, the Department of Science and Technology has established several programs to support R&D in biotechnology and healthcare. The increasing focus on R&D in India has created a favorable environment for the development of vaccines, including malaria vaccines. Several research institutions in India are working on the development of malaria vaccines, and the investment in R&D is likely to drive the growth of the India malaria vaccine market. Moreover, the availability of a skilled workforce and the presence of world-class research institutions in India have also contributed to the growth of the R&D sector. This has facilitated the development of innovative technologies and solutions, including vaccines. Moreover, researchers are working on various approaches to develop malaria vaccines, including subunit vaccines, whole parasite vaccines, and genetically attenuated parasite vaccines. Through this research, scientists can gain a better understanding of the parasite's biology and the immune responses required for protection, which can ultimately lead to the development of effective malaria vaccines. Therefore, the increasing research & development activities in the country is expected to support the growth of the India malaria vaccine market in the forthcoming years.
Segmental Insights
Route of Administration Insights
Based on the route of administration, the intramuscular category is currently dominating the India malaria vaccine market due to several key advantages it offers in terms of efficacy, ease of administration, and acceptance among healthcare professionals. Intramuscular injections allow for better absorption of vaccines compared to subcutaneous or oral routes, which is crucial for ensuring a robust immune response, especially for complex vaccines like those targeting malaria. In addition, the intramuscular route is familiar to healthcare providers across India, making it easier to implement at scale. IM injections are also widely used in existing vaccination programs, providing a sense of standardization that helps ensure smooth integration into national immunization efforts. As malaria vaccination campaigns continue to expand, the familiarity and simplicity of administering vaccines via the IM route are expected to play a pivotal role in encouraging adoption by healthcare professionals and the public. Furthermore, the consistent success of other vaccines delivered intramuscularly in India helps maintain trust in the safety and effectiveness of this administration method for malaria vaccines.
Regional Insights
Based on the region, East India was dominating in India Vaccine Market in 2024. East India, comprising states like West Bengal, Odisha, Bihar, and Assam, is experiencing a significant malaria burden, making it a key region for the malaria vaccine market. These states are known for having high transmission rates of malaria, with large populations living in areas prone to endemic transmission. The prevalence of malaria in these regions, particularly among vulnerable populations such as children and pregnant women, has made it a priority for both government and public health organizations to implement effective prevention strategies, including vaccination. The demand for malaria vaccines is therefore high in East India, where targeted interventions are necessary to control and reduce malaria incidence. The geographical factors and environmental conditions in these states, such as monsoons and high humidity, create ideal breeding grounds for malaria-carrying mosquitoes, exacerbating the disease burden and increasing the urgency of vaccination programs. Consequently, East India's substantial malaria cases have made it the dominant market for malaria vaccines in the country, driving efforts to prioritize vaccine distribution and ensure timely access.
Key Market Players
Gennova Biopharmaceuticals Ltd
Zydus Group
Serum Institute of India Private Limited
Bharat Biotech International Limited
Indian Immunologicals Limited, Inc.
Panacea Biotec
Mynvax
Cadila Pharmaceuticals
Biological E Limited
Sanofi Pasteurs Health
Report Scope:
In this report, India Malaria Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
India Malaria Vaccine Market, By Vaccine Type:
o Pre-Erythrocytic
o Erythrocytic
o Multi-antigen
o Others
India Malaria Vaccine Market, By Route of Administration:
o Intramuscular
o Subcutaneous
o Intradermal
o Others
India Malaria Vaccine Market, By Region:
o North India
o South India
o East India
o West India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present India Malaria Vaccine Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. India Malaria Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others)
5.2.2. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North India Malaria Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Vaccine Type
6.2.2. By Route of Administration
7. South India Malaria Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Vaccine Type
7.2.2. By Route of Administration
8. East India Malaria Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Vaccine Type
8.2.2. By Route of Administration
9. West India Malaria Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Vaccine Type
9.2.2. By Route of Administration
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. Porters Five Forces Analysis
12.1. Competition in the Industry
12.2. Potential of New Entrants
12.3. Power of Suppliers
12.4. Power of Customers
12.5. Threat of Substitute Products/Services
13. Competitive Landscape
13.1. Gennova Biopharmaceuticals Ltd
13.1.1. Business Overview
13.1.2. Company Snapshot
13.1.3. Products & Services
13.1.4. Financials (As Reported)
13.1.5. Recent Developments
13.1.6. Key Personnel Details
13.1.7. SWOT Analysis
13.2. Zydus Group
13.3. Serum Institute of India Private Limited
13.4. Bharat Biotech International Limited
13.5. Indian Immunologicals Limited, Inc.
13.6. Panacea Biotec
13.7. Mynvax
13.8. Cadila Pharmaceuticals
13.9. Biological E Limited
13.10. Sanofi Pasteur
14. Strategic Recommendations
15. About Us & Disclaimer

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE